Posted by Michael Wonder on 11 Dec 2018
The drug industry is headed back to Congress to make its case. Will Democrats keep the door open?
10 December 2018 - With annual revenues of roughly $450 million and an army of some 160 lobbyists, PhRMA has long been described in near mythological terms by both awed opponents and reverent allies: It’s untouchable, it never loses, it can kill a bill before the ink is dry on the first draft.
Suddenly, however, the industry lobbying powerhouse looks far more vulnerable.
More than a dozen current and former staffers and lobbyists connected to the drug industry told STAT that as Democrats take control of the House in January, PhRMA is struggling to preserve its clout.
